CTRI/2017/09/009908已完成2 期
A Randomized open labelled,parallel group study to evaluate the safety and efficacy of Cutisora oil and tablet in fixed dose as well as in combination therapy in patients with mild to moderate psoriasis
Vasu Research Centre0 个研究点目标入组 75 人开始时间: 待定最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Mild to moderate psoriasis
- •Psoriasis area and severity index of less than 20
- •Clinical chemistry and hematology results from visit 1 are within normal limits.
- •Non pregnant female and must agree to use adequate method of contraception during the study.
排除标准
- •Age less than 18 years and not more than 60 years
- •Evidence of alcohol or drug abuse
- •Evidence of unstable forms of psoriasis, including guttate, erthrodermic, exfoliative or pustular psoriasis.
- •Psoriasis area and severity index of more than 20
- •patients suffering from any critical disease of vital organs and chronic diseases like cancer, AIDS,TB etc.
研究者
相似试验
已完成
不适用
A clinical study to study the effect of a herbal formulation in patients with diarrhoea in comparison with oral rehydration therapyCTRI/2018/03/012699Clinfound Clinical Research Services PvtLtd100
尚未招募
2 期
To evaluate the efficacy of cutis capsule and cutis oil in Atopic EczemaCTRI/2017/11/010570Vasu Research Centre
已完成
不适用
A randomized, open-label, parallel-group study to evaluate the safety and pharmacokinetic characteristics in Korean healthy subjectsKCT0003740Korea Yakult Corporation36
已完成
不适用
A randomized, open-label, parallel group study to evaluate the efficacy and safety of the oral administration of Bifidobacterium animalis subsp. lactis LKM512 in patients with atopic dermatitisAtopic dermatitisJPRN-UMIN000005695Kyodo Milk Industry Co. Ltd.50
进行中（未招募）
1 期
The purpose of this clinical trial is to learn about the safety and how well the study medicine (called Abrocitinib) works for the potential treatment of moderate to severe Atopic Dermatitis (AD) in India.EUCTR2024-000141-26-Outside-EU/EEAPfizer Inc.